Clinical Trial Search

Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…

Primary: Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16 — 13.0; 69.1 percentage of…

Primary: The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to…

Primary: Change in Histology

Primary: Number of Participants With Serious Infections, Opportunistic Infections of Interest and Malignancies: Prospective Participants — 0; 0; 0 Participants

Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale

Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants

Primary: Severity of Psoriasis — 2.68; 1.84 units on a scale

Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…

Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants

Primary: Number of Participants With Hematology Abnormalities of Potential Clinical Importance (PCI) — 3; 0; 0; 0 Participants

Primary: proSPI (s) at Week 16 Compared to Baseline — 24.89; 2.34 scores on a scale — p=<0.0001

Primary: Assessment of Clinical Activity by Improvement Score (Using Krueger Criteria): Number of Participants With Good or Excellent Improvement Score Based on Histological…

Primary: Psoriasis Area Severity Index — 5.5; 5.0 score on a scale

Primary: Percentage of Subjects Who Have 75% or More Reduction in [Psoriasis Area-and-severity Index Score (PASI)] (PASI75) — 8; 0 Participants